KRasG12C inhibitors in clinical trials: a short historical perspective

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• KRas is the most frequently mutated oncogene in human cancers.
• Despite decades of research since 1982, no approved drugs directly target Ras in Ras-driven cancers.
• Targeting KRas mutations remains a significant unmet need in cancer therapy.

Purpose of the Study:

• To provide a historical perspective on the development of KRas inhibitors.
• To review promising KRasG12C inhibitors that covalently bind to the mutated protein.
• To highlight recent advancements in targeting KRasG12C-driven cancers.

Main Methods:

• Review of scientific literature on KRas inhibitors.
• Analysis of the mechanism of action for covalent KRasG12C inhibitors.
• Summary of clinical trial progress for novel KRas inhibitors.

Main Results:

• Development of KRasG12C inhibitors that covalently bind to the mutated cysteine residue.
• These inhibitors trap KRas in its inactive GDP-bound state.
• Three independent companies have developed covalent G12C-specific inhibitors that have entered clinical trials.

Conclusions:

• Recent progress in developing covalent KRasG12C inhibitors offers new hope.
• These inhibitors represent a significant advancement in treating KRasG12C-driven cancers.
• Further clinical development is crucial for these promising targeted therapies.